Biohaven Advances Late Stage Clinical Programs And Novel Targets From Neuroinnovation Platforms
Advertisement
- Phase 2/3 clinical trials of troriluzole, a glutamate modulator, in Alzheimer's disease, generalized anxiety disorder, and obsessive-compulsive disorder are all expected to complete enrollment by end of 2019
